Journal of Pharmacology and Drug Development
Login
JPDD
  • Home
  • Articles & Issues
    • Latest Issue
    • All Issues
  • Authors
    • Submit Manuscript
    • Guide for Authors
    • Author Resources
    • Authorship
    • Article Processing Charges (APC)
  • Reviewers
    • Guide for Reviewers
    • Reviewer Resources
    • Become a Reviewer
  • About
    • About Journal
    • Aims and Scope
    • Editorial Team
    • Journal Insights
    • Peer Review Process
    • Publication Ethics
    • Plagiarism
    • Allegations of Misconduct
    • Appeals and Complaints
    • Corrections and Withdrawals
    • Open Access
    • Archiving Policy
    • Announcements
    • Contact

Search Results for cytotoxicity

Article
Selective Cytotoxic Activity of a 5-BromoIndole Carbothioamide (BTIC) Against Human Cancer Cell Lines

Salar A. Fakhri, Abdulkareem Hameed Abd, Alaa H. Abbas

Pages: 285-293

PDF Full Text
Abstract

Background A major limitation is the low selectivity of conventional chemotherapeutic agents, which results in severe toxicity on non-malignant tissues. Scaffolds based on indole have recently been identified as interesting new anticancer candidates but selective cytotoxicity continues to be a key target. Objective The goal of this study was to determine the cytotoxic and specific anticancer effects of a novel 5-bromo-indole-derived carbothioamide (BTIC) on several malignant and non-cancerous cell lines. Methods After a 48-hour treatment, BTIC's antiproliferative effectiveness against human breast cancer (MCF-7), lung cancer (A549), & normal endothelium (HUVEC) cell lines was evaluated using the MTT assay. Data shown as dose-response curves were subjected to nonlinear regression analysis to determine IC50 values. Preferential cytotoxicity was evaluated using the selectivity index (SI). Results In every cell line examined, BTIC had a cytotoxic impact; furthermore, this toxicity was concentration-dependent. This compound exhibited the most powerful activity against A549 cells (IC50 = 3.5 µg/mL), followed by MCF-7 cells IC50 (5.4 µg/mL), and significant cytotoxicity was recorded in HUVEC cells (IC50 = 10.4 µg/mL). A selective cytotoxicity on cancer cells was suggested by these reported SI values (2.97 and 1.93 for A549 and MCF-7, respectively). Conclusion BTIC was also a lead chemical with potent anticancer action against lung cancer cells in vitro, which exhibited high specificity. Therapeutic translation requires additional mechanistic and in vivo studies.

Article
Green Synthesis and Characterization of Gold Nanoparticles from Beta vulgaris L. and Their Cytotoxicity Against MDA-MB-231 and MCF-7 Cancer Cells

Abulfadhel Yahya Al-khafaji, Jenan Hussein Taha, Ibramim Abdullah Mahmood

Pages: 210-222

PDF Full Text
Abstract

With the increasing applications of gold nanoparticles in cancer treatment and medical delivery, it has become necessary to study the biological effects of gold nanoparticles. The study aimed to evaluate the biological effects of gold nanoparticles against the mcf-7 & mda-mb-231 cell line. Gold nanoparticles were characterized using several analytical techniques including X-ray Diffraction (XRD), Ultraviolet-Visible Spectroscopy (UV-VIS), Energy Dispersion X-ray (EDX), Atomic Force Microscopy (AFM), and Filed Emission Scanning Electron Microscopy (FE-SEM).. The characterization results confirmed the successful synthesis of high purity quasi-spherical gold nanoparticles with particle sizes ranging from 38 to 59 nm. The cytotoxic effect of the synthesized AuNPs was investigated using the MTT assay on both MCF-7 and MDA-MB-231 cell lines at six different concentrations. The results indicated a concentration-dependent inhibitory effect of gold nanoparticles on both cancer cell lines, with a high cytotoxic activity observed against the MDA-MB-231 cell line. The results of this study indicate the potential use of gold nanoparticles against various types of cancer cell lines, as well as the potential use of gold nanoparticles in treating cancerous diseases with vivo cell.

1 - 2 of 2 items

Search Parameters

×

The submission system is temporarily under maintenance. Please send your manuscripts to

Go to Editorial Manager
Journal Logo
Journal of Pharmacology and Drug Development

College of Pharmacy | Al-Nahrain University

  • Copyright Policy
  • Terms & Conditions
  • Privacy Policy
  • Accessibility
  • Cookie Settings
Licensing & Open Access

CC BY 4.0 Logo Licensed under CC-BY-4.0

This journal provides immediate open access to its content.

Editorial Manager Logo Elsevier Logo

Peer-review powered by Elsevier’s Editorial Manager®

Copyright © 2026 College of Pharmacy, Al-Nahrain University, its licensors, and contributors. All rights reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.